This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (
TheStreet) -- If China and Europe can take our markets lower, why can't they take them higher as well? That's what Jim Cramer asked
"Mad Money" viewers Monday.
Cramer said that after years of dragging U.S. stocks lower, the evidence is mounting that a turn is at hand overseas, and that should be great news for U.S. stocks.
The media may be focused on Syria and the
Federal Reserve, but Cramer said today's market rally was all about an improving global economy. He said many investors just don't realize many Chinese exports are sold in Europe. With Europe making a slow but steady turn for the better, China will be buoyed as well.
Cramer said he was dead wrong in 2011 when he went bullish on
Ford(F), a stock he owns for his charitable trust,
Action Alerts PLUS
. However, it's not unrealistic to think the automaker could now surpass its 2011 highs of $18 a shares now that Europe has actually become the tailwind he expected.
That's certainly what happened with
Eaton(ETN), another Action Alerts holding, as that stock is almost back to where it was when it disappointed last quarter.
Cummins(CMI) or even
Apple(AAPL), yet another portfolio holding, all of these stocks have Chinese exposure that's being helped by a rising Europe.
Cramer said that when
Joy Global(JOY) delivers hideous guidance and shares rally thereafter, well, "that smells like a bottom." He said that everything from
General Motors(GM) to
General Electric(GE), from the rails to the banks could all be in on this move. Investors just need to pick the right stocks.
Executive Decision: Clay Siegall
In the "Executive Decision" segment, Cramer sat down with Dr. Clay Siegall, chairman, president and CEO of
Seattle Genetics(SGEN - Get Report), one of the many biotech firms leading the charge against cancer. Shares of Seattle Genetics have risen over 88% since Cramer last spoke with Siegall in December.
Siegall said Seattle Genetics currently has over 20 clinical trials in process, both developing new drugs and expanding the uses and indications of their current ones. He said his company's treatments are not providing incremental improvements to the way cancer is being treated, they're saving lives and providing real benefits to a lot of patients.